Ramassamy J, Ayouba A, Thaurignac G, Bilounga Ndongo C, Nnuka P, Betsem E
    
    
    J Infect Dis. 2024; 230(5):e1067-e1076.
  
  
    PMID: 39126336
    
          PMC: 11565877.
    
          DOI: 10.1093/infdis/jiae399.
      
 
                                  
  
    To A, Wong T, Ball A, Lieberman M, Yalley-Ogunro J, Cabus M
    
    
    Vaccine. 2023; 42(3):598-607.
  
  
    PMID: 38158300
    
          PMC: 10872277.
    
          DOI: 10.1016/j.vaccine.2023.12.053.
      
 
                                  
  
    Finch C, Dowling W, King T, Martinez C, Nguyen B, Roozendaal R
    
    
    Vaccines (Basel). 2022; 10(9).
  
  
    PMID: 36146462
    
          PMC: 9503666.
    
          DOI: 10.3390/vaccines10091384.
      
 
                                  
  
    Hargreaves A, Brady C, Mellors J, Tipton T, Carroll M, Longet S
    
    
    Pathogens. 2021; 10(9).
  
  
    PMID: 34578233
    
          PMC: 8468515.
    
          DOI: 10.3390/pathogens10091201.
      
 
                                  
  
    Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P
    
    
    PLoS Negl Trop Dis. 2020; 14(10):e0008699.
  
  
    PMID: 33095766
    
          PMC: 7641473.
    
          DOI: 10.1371/journal.pntd.0008699.
      
 
                              
              
                              
                                      
  Long-lasting severe immune dysfunction in Ebola virus disease survivors.
  
    Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum B, Durand M
    
    
    Nat Commun. 2020; 11(1):3730.
  
  
    PMID: 32709840
    
          PMC: 7381622.
    
          DOI: 10.1038/s41467-020-17489-7.
      
 
                                          
                                                          
  Sources and symptoms of stress among nurses in the first Chinese anti-Ebola medical team during the Sierra Leone aid mission: A qualitative study.
  
    Liu C, Wang H, Zhou L, Xie H, Yang H, Yu Y
    
    
    Int J Nurs Sci. 2019; 6(2):187-191.
  
  
    PMID: 31406890
    
          PMC: 6608674.
    
          DOI: 10.1016/j.ijnss.2019.03.007.
      
 
                                          
                                                          
  Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
  
    Sobarzo A, Stonier S, Radinsky O, Gelkop S, Kuehne A, Edri A
    
    
    EBioMedicine. 2019; 46:215-226.
  
  
    PMID: 31326432
    
          PMC: 6710910.
    
          DOI: 10.1016/j.ebiom.2019.07.021.
      
 
                                          
                                                          
  First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain.
  
    de Arellano E, Sanchez-Lockhart M, Perteguer M, Bartlett M, Ortiz M, Campioli P
    
    
    Viruses. 2019; 11(4).
  
  
    PMID: 31010201
    
          PMC: 6521100.
    
          DOI: 10.3390/v11040360.
      
 
                                          
                                                          
  Achieving cross-reactivity with pan-ebolavirus antibodies.
  
    King L, Milligan J, West B, Schendel S, Saphire E
    
    
    Curr Opin Virol. 2019; 34:140-148.
  
  
    PMID: 30884329
    
          PMC: 6611554.
    
          DOI: 10.1016/j.coviro.2019.01.003.
      
 
                                          
                                                          
  Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease.
  
    Babirye P, Musubika C, Kirimunda S, Downing R, Lutwama J, Mbidde E
    
    
    BMC Infect Dis. 2018; 18(1):498.
  
  
    PMID: 30285648
    
          PMC: 6171133.
    
          DOI: 10.1186/s12879-018-3409-x.
      
 
                                          
                                                          
  The structural basis for filovirus neutralization by monoclonal antibodies.
  
    King L, West B, Schendel S, Saphire E
    
    
    Curr Opin Immunol. 2018; 53:196-202.
  
  
    PMID: 29940415
    
          PMC: 6141344.
    
          DOI: 10.1016/j.coi.2018.05.001.
      
 
                                          
                                                          
  Seroprevalence of Ebola virus infection in Bombali District, Sierra Leone.
  
    Mafopa N, Russo G, Guetiya Wadoum R, Iwerima E, Batwala V, Giovanetti M
    
    
    J Public Health Afr. 2018; 8(2):732.
  
  
    PMID: 29456826
    
          PMC: 5812302.
    
          DOI: 10.4081/jphia.2017.732.
      
 
                                          
                                                          
  Immune barriers of Ebola virus infection.
  
    McElroy A, Muhlberger E, Munoz-Fontela C
    
    
    Curr Opin Virol. 2018; 28:152-160.
  
  
    PMID: 29452995
    
          PMC: 5886007.
    
          DOI: 10.1016/j.coviro.2018.01.010.
      
 
                                          
                                                          
  Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection.
  
    Rimoin A, Lu K, Bramble M, Steffen I, Doshi R, Hoff N
    
    
    J Infect Dis. 2017; 217(2):223-231.
  
  
    PMID: 29253164
    
          PMC: 5853670.
    
          DOI: 10.1093/infdis/jix584.
      
 
                                          
                                                          
  Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
  
    Radinsky O, Edri A, Brusilovsky M, Fedida-Metula S, Sobarzo A, Gershoni-Yahalom O
    
    
    Sci Rep. 2017; 7(1):6054.
  
  
    PMID: 28729706
    
          PMC: 5519693.
    
          DOI: 10.1038/s41598-017-06226-8.
      
 
                                          
                                                          
  Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.
  
    Stonier S, Herbert A, Kuehne A, Sobarzo A, Habibulin P, Dahan C
    
    
    J Exp Med. 2017; 214(9):2563-2572.
  
  
    PMID: 28724616
    
          PMC: 5584125.
    
          DOI: 10.1084/jem.20170161.
      
 
                                          
                                                          
  Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus.
  
    Glynn J, Bower H, Johnson S, Houlihan C, Montesano C, Scott J
    
    
    Lancet Infect Dis. 2017; 17(6):645-653.
  
  
    PMID: 28256310
    
          PMC: 6520246.
    
          DOI: 10.1016/S1473-3099(17)30111-1.
      
 
                                          
                                                          
  The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.
  
    Lubaki N, Younan P, Santos R, Meyer M, Iampietro M, Koup R
    
    
    PLoS Pathog. 2016; 12(12):e1006031.
  
  
    PMID: 27930745
    
          PMC: 5145241.
    
          DOI: 10.1371/journal.ppat.1006031.
      
 
                                          
                                                          
  Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses.
  
    Natesan M, Jensen S, Keasey S, Kamata T, Kuehne A, Stonier S
    
    
    Clin Vaccine Immunol. 2016; 23(8):717-24.
  
  
    PMID: 27335383
    
          PMC: 4979172.
    
          DOI: 10.1128/CVI.00107-16.